Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
Authors:
Open Access
- 31 May 2021
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 13 (1) , 1-15
Abstract
Background: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulating DNA in plasma that is tumor-derived (i.e., cfDNA tumor fraction). We hypothesized that cfDNA tumor fraction could inform the interpretation of negative cfDNA results and guide the choice of subsequent assays of greater genomic breadth or depth.Methods: Plasma samples collected from 118 metastatic cancer patients were analyzed with cf-IMPACT, a modified version of the FDA-authorized MSK-IMPACT tumor test that can detect genomic alterations in 410 cancer-associated genes. Shallow whole genome sequencing (sWGS) was also performed in the same samples to estimate cfDNA tumor fraction based on genome-wide copy number alterations usingz-score statistics. Plasma samples with no somatic alterations detected by cf-IMPACT were triaged based on sWGS-estimated tumor fraction for analysis with either a less comprehensive but more sensitive assay (MSK-ACCESS) or broader whole exome sequencing (WES).Results: cfDNA profiling using cf-IMPACT identified somatic mutations in 55/76 (72%) patients for whom MSK-IMPACT tumor profiling data were available. A significantly higher concordance of mutational profiles and tumor mutational burden (TMB) was observed between plasma and tumor profiling for plasma samples with a high tumor fraction (z-score≥5). In the 42 patients from whom tumor data was not available, cf-IMPACT identified mutations in 16/42 (38%). In total, cf-IMPACT analysis of plasma revealed mutations in 71/118 (60%) patients, with clinically actionable alterations identified in 30 (25%), including therapeutic targets of FDA-approved drugs. Of the 47 samples without alterations detected and low tumor fraction (z-scorez-score≥5) were analyzed by WES, which identified mutational signatures and alterations in potential oncogenic drivers not covered by the cf-IMPACT panel. Overall, we identified mutations in 90/118 (76%) patients in the entire cohort using the three complementary plasma profiling approaches.Conclusions: cfDNA tumor fraction can inform the interpretation of negative cfDNA results and guide the selection of subsequent sequencing platforms that are most likely to identify clinically-relevant genomic alterations.Keywords
Funding Information
- National Cancer Institute (P30 CA008748)
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- Cycle for Survival
- Prostate Cancer Foundation
This publication has 42 references indexed in Scilit:
- Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS ApproachClinical Chemistry, 2015
- DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cellsMolecular Cancer, 2014
- Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testingProceedings of the National Academy of Sciences, 2014
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence dataBioinformatics, 2013
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNANature, 2013
- Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencingGenome Medicine, 2013
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Establishment of tumor‐specific copy number alterations from plasma DNA of patients with cancerInternational Journal of Cancer, 2013